Alan Lichtin, MD, Oncology, Cleveland, OH, Cleveland Clinic

AlanELichtinMD

Oncology Cleveland, OH

Hematologic Oncology

Staff Physician, Cleveland Clinic Department of Hematologic Oncology and Blood Disorders. Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine

Dr. Lichtin is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lichtin's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology/Oncology, 1983 - 1986
  • Case Western Reserve University - University Hospitals
    Case Western Reserve University - University HospitalsResidency, Internal Medicine, 1980 - 1983
  • University of Cincinnati College of Medicine
    University of Cincinnati College of MedicineClass of 1980

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2003 - 2020
  • NY State Medical License
    NY State Medical License 2002 - Present
  • MI State Medical License
    MI State Medical License 2002 - 2021
  • IL State Medical License
    IL State Medical License 2002 - 2005
  • PA State Medical License
    PA State Medical License 1983 - 2016
  • OH State Medical License
    OH State Medical License 1982 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
  • Top MD Consumers Checkbook

Publications & Presentations

PubMed

Abstracts/Posters

  • Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity
    Alan Lichtin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine
    Alan Lichtin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation
    Alan Lichtin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Press Mentions

  • ASH Recommends Changes to Continuing Board Certification
    ASH Recommends Changes to Continuing Board CertificationMarch 1st, 2019
  • 6 Signs You Might Have This Rare Bruising and Bleeding Disorder
    6 Signs You Might Have This Rare Bruising and Bleeding DisorderDecember 14th, 2017
  • ASH 2018: Dec 1-4
    ASH 2018: Dec 1-4December 1st, 2017
  • Join now to see all

Professional Memberships

Hospital Affiliations